Find immune signs identifying Parkinson
- Trial ID
- NCT04239079
- Official Title
- Autoimmune Features of Neurodegenerative Disorders
- Goal
- Find immune signs identifying Parkinson
- Status
- RECRUITING
- Sponsor
- Columbia University
- Study Type
- OBSERVATIONAL
- Enrollment
- 120 participants
- Conditions
- Parkinson Disease, Alzheimer Disease, Mild Cognitive Impairment
Plain-Language Summary
The goal is to look for autoimmune or immune-system patterns that might be linked to Parkinson's, Alzheimer's, and amnestic mild cognitive impairment, to better understand whether immune responses play a role in these brain disorders. Instead of testing a treatment, researchers will collect genetic data and immune-related measurements along with clinical assessments to compare immune markers and genotypes across people with PD, AD/aMCI, and age-matched healthy volunteers. The idea is to identify immune pathways or biomarkers that could guide future treatments or help distinguish disease types. Enrollment is for people aged 55 to 90, with about 30 in each group: PD participants with motor onset between 50 and 75 who show classic signs and dopaminergic benefit, people with mild AD/aMCI (MMSE about 20,26), and healthy controls; anyone with autoimmune disease, major immune disorders, recent cancer, or on chronic immune-modulating therapy is excluded.
Locations
- Columbia University Medical Center, New York, New York, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to look for autoimmune or immune-system patterns that might be linked to Parkinson's, Alzheimer's, and amnestic mild cognitive impairment, to better understand whether immune responses play a role in these brain disorders. Instead of testing a treatment, researchers will collect genetic data and immune-related measurements along with clinical assessments to compare immune markers and genotypes across people with PD, AD/aMCI, and age-matched healthy volunteers. The idea is to identify immune pathways or biomarkers that could guide future treatments or help distinguish disease types. Enrollment is for people aged 55 to 90, with about 30 in each group: PD participants with motor onset between 50 and 75 who show classic signs and dopaminergic benefit, people with mild AD/aMCI (MMSE about 20,26), and healthy controls; anyone with autoimmune disease, major immune disorders, recent cancer, or on chronic immune-modulating therapy is excluded.
- Who can participate?
- Participants must be between 55 Years and 90 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 7 years and 1 month.